Tech stocks surge as Nvidia's AI investments boost semiconductor demand, driving gains for ASML, Samsung, and other firms. Analysts warn of potential market volatility.
Codelco reduces its 2025 copper production forecast after a tragic mine incident, while planning a potential bond sale amidst rising copper prices and investor optimism.
Pfizer acquires Metsera for $4.9 billion to boost its presence in the obesity drug market, eyeing a lucrative sector projected to reach $100 billion by 2030.
Super Typhoon Ragasa threatens to delay Zijin Gold's massive IPO in Hong Kong, illustrating the impact of natural disasters on financial markets and regulatory challenges.
Trump calls Charlie Kirk a "martyr for American freedom" during a memorial in Arizona, blending emotional tributes with political controversy and criticisms of liberal ideologies.
FedEx revitalizes partnership with Amazon, reshaping e-commerce logistics amid FedEx's efficiency drive and UPS's strategic pullback, highlighting shifting industry dynamics and competitive tensions.
JPMorgan highlights India's strong IPO market and economic resilience amid tariff and visa challenges, predicting continued growth despite international obstacles.
Saudi Arabia attracts global investment with Stride Ventures committing $200M, a local Airbnb rival planning an IPO, and stock market reforms boosting foreign ownership.
UK Big Pharma pulls investments, challenging the NHS's drug pricing controls, raising concerns over the UK's competitiveness in life sciences and potential impacts on public health policy.
The Trump administration faces backlash for suggesting Tylenol use during pregnancy links to autism, sparking concerns from UK health officials and healthcare professionals worldwide.
Rising oil prices hit global markets due to increased Russian crude exports, refinery strikes, and potential diesel curbs, creating a volatile energy landscape.
Bristol Myers Squibb's new schizophrenia drug, Cobenfy, priced at $22,500 annually, raises debate on UK drug pricing and regulatory approval challenges amid government cost-cutting pressures.